## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	pplicat	ion of: Dario Neri et al.					
Serial	No.: 10	/821,930	Group Art	Unit: 1645			
Filed:	April 12	2, 2004	Examiner:	Virginia Allen Portner			
For: SPECIFIC BINDING MOLECULES FOR SCINTIGRAPHY, CONJUGATES CONTAINING THEM AND THERAPEUTIC METHOD FOR TREATMENT OF ANGIOGENESIS							
<u>INFO</u>	RMAT	TION DISCLOSURE STATEMENT UNDE	R 37 CFR §	§ 1.56, 1.97 and 1.98			
P.O. B	ox 1450	r for Patents 0 (A 22313-1450					
Sir:							
This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:							
<u>Fimin</u>	g and Fe	<u>ees</u>					
		Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:					
		within three months of the filing date of a nat under § 1.53(d);	ional applica	ation other than a CPA			
		within three months of the actual filing dat application; OR	e of the nat	ional phase of a PCT			
		before the mailing of a first substantive office RCE).	action (incl	uding after filing of an			
$\boxtimes$	Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the pespecified in 37 C.F.R. § 1.97(b), but before the mailing date of:			s filed after the periods			
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Qua a notice of allowance under 37 C.F.R. § 1.31	-	P § 609(B)(2); OR			

		is accompanied by:				
			the statement as specified in 37 C.F.R. § 1.97(e) set out below;			
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p); or			
			payment by credit card via EFS covering the fee of \$180.00 under 37 C.F.R. § 1.17(p); or			
		37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing f the following actions which have not been withdrawn:				
		a final	action under 37 C.F.R. § 1.113;			
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);			
		OR a ı	notice of allowance under 37 C.F.R. § 1.311;			
	AND	is filed on or before payment of the issue fee; AND is accompanied by:				
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).			
Staten	nents U	nder 37	C.F.R. 1.97(e)			
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or			
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.			
Cited Materials						
		Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).				
		Copies of Non Final and Final Rejections listed in other U.S. application of patents are not attached. Applicants request that the Examiner obtain them from				

		the USPTO PAIR system and review them. If copies are requested, Applicants will supply them as a supplement.				
	$\boxtimes$	Not required by 37 CFR § 1.98.				
	$\boxtimes$	Copies of the materials listed are attached (except for the foregoing).				
Non-I	English 1	Language References				
	$\boxtimes$	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).				
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:				
		<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> </ul>				
		A = document defining the general state of the art O = non-written disclosure				
		P = intercalated document				
		T = document cited to understand the theory or principle underlying the invention				
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date				
		D = cited in the application L = cited for another reason				
		& = publication of member of same patent family				
		Translation of other relevant information on foreign search report				
<u>Other</u>	Informa	<u>ation</u>				
Payme	ent of F	ees Due (If Any):				
	A chee	check for \$ covering the fee identified above is attached.				
$\boxtimes$	Payme	ment by credit card via EFS for \$180.00 covering the fee identified above.				
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.				

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402.

Respectfully submitted,

/Anthony J. Zelano/

Anthony J. Zelano, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: ELLIS-0002-C01

Date: May 6, 2010

AJZ:cac